About Tolero Pharma
Tolero Pharma is a company based in Lehi (United States) founded in 2011 was acquired by Sumitomo Dainippon Pharma in December 2016. Tolero Pharma has raised $48.23 million across 4 funding rounds from investors including Alger and Sumitomo Dainippon Pharma. The company has 17 employees as of December 31, 2016. Tolero Pharma operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Lehi, United States
- Employees 17 as on 31 Dec, 2016
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$48.23 M (USD)
in 4 rounds
-
Latest Funding Round
$8.2 M (USD), Series B
Dec 05, 2014
-
Investors
Alger
& 1 more
-
Employee Count
17
as on Dec 31, 2016
-
Acquired by
Sumitomo Dainippon Pharma
(Dec 21, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Tolero Pharma
Tolero Pharma has successfully raised a total of $48.23M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $8.2 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tolero Pharma
Tolero Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Alger and Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
ESG investments are managed by this venture capital firm.
|
Locked | Locked | Locked | |
|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
|
Locked | Locked | Locked |
Investor details for Tolero Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tolero Pharma
Investment portfolio details for Tolero Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tolero Pharma
Detailed financials for Tolero Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tolero Pharma Comparisons
Peer comparison for Tolero Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tolero Pharma
Tolero Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of Tolero Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tolero Pharma
Complete news archive for Tolero Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tolero Pharma
Tolero Pharma was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Tolero Pharma is headquartered in Lehi, United States. It is registered at Lehi, Utah, United States.
Tolero Pharma is a funded company, having raised a total of $48.23M across 4 funding rounds to date.
As of Dec 31, 2016, the latest employee count at Tolero Pharma is 17.
Tolero Pharma was founded in 2011 and is based in Lehi, United States. Operations focus on the development of therapeutics targeting biological drivers of blood disorders, including leukemias and anemia. The pipeline features an immunotherapeutic cancer vaccine as the lead candidate, along with inhibitors for AXL, CDK9, ALK2, PIM, and BTK. Efforts center on oncology within the biopharmaceutical sector.
Tolero Pharma's top competitors include Moderna, BeiGene and Strand Therapeutics.
Tolero Pharma has 2 investors. Key investors include Alger, and Sumitomo Dainippon Pharma.